Cargando…
LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
Radiotherapy, chemotherapy, autologous/allogeneic stem cell transplantation, and targeted drug therapy are currently available therapeutic options for multiple myeloma (MM), but the clinical outcome remains unsatisfactory owing to frequent occurrence of drug resistance. Anti apoptosis is one of the...
Autores principales: | Pan, Yafang, Zhang, Yu, Liu, Wenwen, Huang, Yan, Shen, Xianjuan, Jing, Rongrong, Pu, Jiang, Wang, Xudong, Ju, Shaoqing, Cong, Hui, Chen, Hongmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365572/ https://www.ncbi.nlm.nih.gov/pubmed/30728351 http://dx.doi.org/10.1038/s41419-018-1219-0 |
Ejemplares similares
-
Circulating lncRNA DANCR as a potential auxillary biomarker for the diagnosis and prognostic prediction of colorectal cancer
por: Shen, Xianjuan, et al.
Publicado: (2020) -
PCAT‐1 promotes cell growth by sponging miR‐129 via MAP3K7/NF‐κB pathway in multiple myeloma
por: Shen, Xianjuan, et al.
Publicado: (2020) -
Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib
por: Tang, Ju‐xian, et al.
Publicado: (2021) -
Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways
por: Shen, Xianjuan, et al.
Publicado: (2019) -
Aberrant lncRNA Expression in Multiple Myeloma
por: Meng, Hui, et al.
Publicado: (2018)